SK34196A3 - Piperidine derivatives, preparation method thereof, piperidine derivatives as medicaments and pharmaceutical compositions containing these derivatives - Google Patents

Piperidine derivatives, preparation method thereof, piperidine derivatives as medicaments and pharmaceutical compositions containing these derivatives Download PDF

Info

Publication number: SK34196A3
Authority: SK; Slovakia
Prior art keywords: methyl; mixture; formula; compound; fluoro
Prior art date: 1995-03-13

Application number

SK341-96A

Other languages

English (en)

Slovak (sk)

Inventor

Luc Even

Samir Jegham

Gerard Defosse

Michel Aletru

Original Assignee

Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-13

Filing date

1996-03-12

Publication date

1996-10-02

1996-03-12 Application filed by Synthelabo filed Critical Synthelabo

1996-10-02 Publication of SK34196A3 publication Critical patent/SK34196A3/sk

Links

150000003053 piperidines Chemical class 0.000 title claims description 5
238000002360 preparation method Methods 0.000 title claims description 5
239000003814 drug Substances 0.000 title claims 2
239000008194 pharmaceutical composition Substances 0.000 title claims 2
150000003839 salts Chemical class 0.000 claims abstract description 9
239000002253 acid Substances 0.000 claims abstract description 7
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052801 chlorine Inorganic materials 0.000 claims abstract description 5
229910052731 fluorine Inorganic materials 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 78
239000000203 mixture Substances 0.000 claims description 58
PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical compound C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 claims description 17
-1 racemic mixtures Chemical class 0.000 claims description 8
238000000034 method Methods 0.000 claims description 6
150000007513 acids Chemical class 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims 2
125000005843 halogen group Chemical group 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000002904 solvent Substances 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 15
239000000243 solution Substances 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
230000008018 melting Effects 0.000 description 14
238000002844 melting Methods 0.000 description 14
239000000741 silica gel Substances 0.000 description 14
229910002027 silica gel Inorganic materials 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
239000000460 chlorine Substances 0.000 description 11
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
239000012074 organic phase Substances 0.000 description 10
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
238000010992 reflux Methods 0.000 description 9
238000003756 stirring Methods 0.000 description 9
239000000725 suspension Substances 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
239000000872 buffer Substances 0.000 description 8
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
229910021529 ammonia Inorganic materials 0.000 description 7
239000005457 ice water Substances 0.000 description 7
239000002244 precipitate Substances 0.000 description 7
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
238000001953 recrystallisation Methods 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 5
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 5
230000009870 specific binding Effects 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
OAAFGNFILDPKMU-UHFFFAOYSA-N 4-(5-methyl-1h-imidazol-4-yl)piperidine Chemical compound N1C=NC(C2CCNCC2)=C1C OAAFGNFILDPKMU-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 4
239000008188 pellet Substances 0.000 description 4
ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 4
239000007787 solid Substances 0.000 description 4
JYCQMEKALUHIAL-YFKPBYRVSA-N (3s)-7-fluoro-3-methyl-5-nitro-3,4-dihydro-2h-1,4-benzoxazine Chemical compound FC1=CC([N+]([O-])=O)=C2N[C@@H](C)COC2=C1 JYCQMEKALUHIAL-YFKPBYRVSA-N 0.000 description 3
KZAHNTPKMFIPEI-UHFFFAOYSA-N 2h-1,4-benzoxazin-8-amine Chemical compound N1=CCOC2=C1C=CC=C2N KZAHNTPKMFIPEI-UHFFFAOYSA-N 0.000 description 3
NNDJCSXUAYKMAA-UHFFFAOYSA-N 4-(1h-imidazol-5-yl)piperidine Chemical compound C1CNCCC1C1=CN=CN1 NNDJCSXUAYKMAA-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
235000011114 ammonium hydroxide Nutrition 0.000 description 3
238000005984 hydrogenation reaction Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
JTXAGNZUUMTJSO-LURJTMIESA-N (2s)-1-(2-bromo-5-fluorophenoxy)propan-2-amine Chemical compound C[C@H](N)COC1=CC(F)=CC=C1Br JTXAGNZUUMTJSO-LURJTMIESA-N 0.000 description 2
SNGUVOWZWOAOIE-LURJTMIESA-N (3s)-3-methyl-5-nitro-3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC([N+]([O-])=O)=C2N[C@@H](C)COC2=C1 SNGUVOWZWOAOIE-LURJTMIESA-N 0.000 description 2
YDBFCOKWYACPMU-YFKPBYRVSA-N (3s)-3-methyl-7-nitro-3,4-dihydro-2h-1,4-benzoxazin-5-amine Chemical compound [O-][N+](=O)C1=CC(N)=C2N[C@@H](C)COC2=C1 YDBFCOKWYACPMU-YFKPBYRVSA-N 0.000 description 2
SOPUKLZQTCAERK-YFKPBYRVSA-N (3s)-7-fluoro-3-methyl-3,4-dihydro-2h-1,4-benzoxazin-5-amine Chemical compound FC1=CC(N)=C2N[C@@H](C)COC2=C1 SOPUKLZQTCAERK-YFKPBYRVSA-N 0.000 description 2
FUNJHONCFBDKGW-UHFFFAOYSA-N 1,4-benzoxazin-2-one Chemical compound C1=CC=C2OC(=O)C=NC2=C1 FUNJHONCFBDKGW-UHFFFAOYSA-N 0.000 description 2
SOOMJUDZYOYKEU-ZETCQYMHSA-N 1-[(3s)-7-fluoro-3-methyl-2,3-dihydro-1,4-benzoxazin-4-yl]ethanone Chemical compound FC1=CC=C2N(C(C)=O)[C@@H](C)COC2=C1 SOOMJUDZYOYKEU-ZETCQYMHSA-N 0.000 description 2
HUVAOAVBKOVPBZ-UHFFFAOYSA-N 2-bromo-5-fluorophenol Chemical compound OC1=CC(F)=CC=C1Br HUVAOAVBKOVPBZ-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
229920002873 Polyethylenimine Polymers 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
238000009835 boiling Methods 0.000 description 2
ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 2
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
238000006396 nitration reaction Methods 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229910003446 platinum oxide Inorganic materials 0.000 description 2
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000002295 serotoninergic effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
YQGHQGFMVOEZAA-YFKPBYRVSA-N (3s)-3-methyl-5,7-dinitro-3,4-dihydro-2h-1,4-benzoxazine Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C2N[C@@H](C)COC2=C1 YQGHQGFMVOEZAA-YFKPBYRVSA-N 0.000 description 1
KSRUXROHBAQLQO-YFKPBYRVSA-N (3s)-7-chloro-3-methyl-5-nitro-3,4-dihydro-2h-1,4-benzoxazine Chemical compound ClC1=CC([N+]([O-])=O)=C2N[C@@H](C)COC2=C1 KSRUXROHBAQLQO-YFKPBYRVSA-N 0.000 description 1
UVWNORIHOSLHIO-LURJTMIESA-N (3s)-7-fluoro-3-methyl-3,4-dihydro-2h-1,4-benzoxazine Chemical compound FC1=CC=C2N[C@@H](C)COC2=C1 UVWNORIHOSLHIO-LURJTMIESA-N 0.000 description 1
DHJATIMYGGMFCZ-YFKPBYRVSA-N (3s)-7-fluoro-3-methyl-6-nitro-3,4-dihydro-2h-1,4-benzoxazine Chemical compound FC1=C([N+]([O-])=O)C=C2N[C@@H](C)COC2=C1 DHJATIMYGGMFCZ-YFKPBYRVSA-N 0.000 description 1
IQRUSQUYPCHEKN-UHFFFAOYSA-N 2-iodobutane Chemical compound CCC(C)I IQRUSQUYPCHEKN-UHFFFAOYSA-N 0.000 description 1
LNNXFUZKZLXPOF-UHFFFAOYSA-N 2-methylpropyl nitrate Chemical compound CC(C)CO[N+]([O-])=O LNNXFUZKZLXPOF-UHFFFAOYSA-N 0.000 description 1
CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
PTWPQXDAIQWYJY-UHFFFAOYSA-N 6-fluoro-11-methyl-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-2-one Chemical compound CC1CCC2=CC(F)=CC3=C2N1C(=O)N3 PTWPQXDAIQWYJY-UHFFFAOYSA-N 0.000 description 1
DJQMOPMWBQOIBA-UHFFFAOYSA-N 6-fluoro-11-methyl-2-[4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl]-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene Chemical compound C=12N3C(C)CCC2=CC(F)=CC=1N=C3N(CC1)CCC1C=1N=CNC=1C DJQMOPMWBQOIBA-UHFFFAOYSA-N 0.000 description 1
BDCCXYVTXRUGAN-UHFFFAOYSA-N 6-fluoro-2-methyl-1,2,3,4-tetrahydroquinoline Chemical compound FC1=CC=C2NC(C)CCC2=C1 BDCCXYVTXRUGAN-UHFFFAOYSA-N 0.000 description 1
ZKBYYUCLCRPWFR-UHFFFAOYSA-N 6-fluoro-2-methyl-8-nitro-1,2,3,4-tetrahydroquinoline Chemical compound FC1=CC([N+]([O-])=O)=C2NC(C)CCC2=C1 ZKBYYUCLCRPWFR-UHFFFAOYSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
YPNKTJRTQWEYMM-BTJKTKAUSA-N C(\C=C/C(=O)O)(=O)O.O1CC=NC2=C1C=CC=C2 Chemical compound C(\C=C/C(=O)O)(=O)O.O1CC=NC2=C1C=CC=C2 YPNKTJRTQWEYMM-BTJKTKAUSA-N 0.000 description 1
206010007270 Carcinoid syndrome Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KMJNSLVZTVQORV-OLAZFDQMSA-N Cl[C@@H]1OC2=C(NC1C)C(=CC=C2)[N+](=O)[O-] Chemical compound Cl[C@@H]1OC2=C(NC1C)C(=CC=C2)[N+](=O)[O-] KMJNSLVZTVQORV-OLAZFDQMSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000019430 Motor disease Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000018569 Respiratory Tract disease Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
MOZPSIXKYJUTKI-RLXJOQACSA-N [1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 1-(tritritiomethyl)indole-3-carboxylate Chemical compound C12=CC=CC=C2N(C([3H])([3H])[3H])C=C1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1 MOZPSIXKYJUTKI-RLXJOQACSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000007661 gastrointestinal function Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000002011 intestinal secretion Anatomy 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004452 microanalysis Methods 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910052979 sodium sulfide Inorganic materials 0.000 description 1
GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
WFPMURSFOKIWHE-UHFFFAOYSA-N tert-butyl 6-fluoro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylate Chemical compound FC=1C=C2CCC(N(C2=CC1)C(=O)OC(C)(C)C)C WFPMURSFOKIWHE-UHFFFAOYSA-N 0.000 description 1
POBUPRFERVELQJ-UHFFFAOYSA-N tert-butyl 6-fluoro-2-methyl-8-nitro-3,4-dihydro-2H-quinoline-1-carboxylate Chemical compound FC=1C=C2CCC(N(C2=C(C1)[N+](=O)[O-])C(=O)OC(C)(C)C)C POBUPRFERVELQJ-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
HDDNYFLPWFSBLN-ZSHCYNCHSA-N tropanyl 3,5-dimethylbenzoate Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(C)=CC(C)=C1 HDDNYFLPWFSBLN-ZSHCYNCHSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Hydrogenated Pyridines (AREA)

SK341-96A 1995-03-13 1996-03-12 Piperidine derivatives, preparation method thereof, piperidine derivatives as medicaments and pharmaceutical compositions containing these derivatives SK34196A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9502863A FR2731708B1 (fr)	1995-03-13	1995-03-13	Derives de piperidine, leur procede de preparation et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
SK34196A3 true SK34196A3 (en)	1996-10-02

Family

ID=9476960

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK341-96A SK34196A3 (en)	1995-03-13	1996-03-12	Piperidine derivatives, preparation method thereof, piperidine derivatives as medicaments and pharmaceutical compositions containing these derivatives

Country Status (15)

Country	Link
EP (1)	EP0732334A1 (cs)
JP (1)	JPH08269058A (cs)
KR (1)	KR960034205A (cs)
CN (1)	CN1140174A (cs)
AU (1)	AU4800896A (cs)
CA (1)	CA2171579A1 (cs)
CZ (1)	CZ75496A3 (cs)
FR (1)	FR2731708B1 (cs)
HU (1)	HUP9600624A2 (cs)
IL (1)	IL117455A0 (cs)
NO (1)	NO961000L (cs)
NZ (1)	NZ286164A (cs)
PL (1)	PL313204A1 (cs)
SK (1)	SK34196A3 (cs)
ZA (1)	ZA961994B (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2231887A1 (en) *	1995-09-18	1997-03-27	Glaxo Group Limited	5-ht3 receptor antagonists for dyskinesia
TW527186B (en)	1996-03-19	2003-04-11	Janssen Pharmaceutica Nv	Fused imidazole derivatives as multidrug resistance modulators
FR2801589A1 (fr) *	1999-11-25	2001-06-01	Sanofi Synthelabo	Derives de 2-arylquinoleine, leur preparation et leur application en therapeutique
HRP20030081A2 (en)	2000-08-08	2005-02-28	Sanofi-Aventis	Benzimidazole derivatives, preparation and therapeutic use thereof
FR2816619B1 (fr) *	2000-11-15	2003-01-31	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816942B1 (fr)	2000-11-23	2003-05-09	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816941B1 (fr) *	2000-11-23	2003-01-31	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
US9227985B2 (en) *	2013-03-15	2016-01-05	Incyte Corporation	Tricyclic heterocycles as bet protein inhibitors
EP3019502B1 (en) *	2013-07-08	2017-05-17	Incyte Holdings Corporation	Tricyclic heterocycles as bet protein inhibitors
US9399640B2 (en)	2013-11-26	2016-07-26	Incyte Corporation	Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en)	2013-12-19	2016-04-12	Incyte Corporation	Tricyclic heterocycles as BET protein inhibitors
MY180775A (en)	2014-04-23	2020-12-09	Incyte Corp	1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
US9527864B2 (en)	2014-09-15	2016-12-27	Incyte Corporation	Tricyclic heterocycles as BET protein inhibitors
WO2017075377A1 (en)	2015-10-29	2017-05-04	Incyte Corporation	Amorphous solid form of a bet protein inhibitor
KR102643344B1 (ko)	2016-06-20	2024-03-07	인사이트 코포레이션	Bet 저해제의 결정질 고체 형태
US11535633B2 (en) *	2018-06-28	2022-12-27	Jiangsu Hengrui Medicine Co., Ltd.	Fused tricyclic heterocycle compounds and therapeutic uses thereof
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2674855B1 (fr) *	1991-04-03	1994-01-14	Synthelabo	Derives de piperidine, leur preparation et leur application en therapeutique.
FR2696176B1 (fr) *	1992-09-28	1994-11-10	Synthelabo	Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
FR2710915B1 (fr) *	1993-10-04	1995-11-24	Synthelabo	Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.

1995
- 1995-03-13 FR FR9502863A patent/FR2731708B1/fr not_active Expired - Fee Related
1996
- 1996-03-04 EP EP96400452A patent/EP0732334A1/fr not_active Withdrawn
- 1996-03-12 CZ CZ96754A patent/CZ75496A3/cs unknown
- 1996-03-12 AU AU48008/96A patent/AU4800896A/en not_active Abandoned
- 1996-03-12 ZA ZA961994A patent/ZA961994B/xx unknown
- 1996-03-12 NZ NZ286164A patent/NZ286164A/en unknown
- 1996-03-12 NO NO961000A patent/NO961000L/no unknown
- 1996-03-12 CA CA002171579A patent/CA2171579A1/en not_active Abandoned
- 1996-03-12 PL PL96313204A patent/PL313204A1/xx unknown
- 1996-03-12 CN CN96107315A patent/CN1140174A/zh active Pending
- 1996-03-12 KR KR1019960006462A patent/KR960034205A/ko not_active Withdrawn
- 1996-03-12 HU HU9600624A patent/HUP9600624A2/hu unknown
- 1996-03-12 JP JP8054560A patent/JPH08269058A/ja active Pending
- 1996-03-12 IL IL11745596A patent/IL117455A0/xx unknown
- 1996-03-12 SK SK341-96A patent/SK34196A3/sk unknown

Also Published As

Publication number	Publication date
PL313204A1 (en)	1996-09-16
NZ286164A (en)	1996-11-26
FR2731708A1 (fr)	1996-09-20
FR2731708B1 (fr)	1997-04-30
CZ75496A3 (en)	1996-10-16
NO961000L (no)	1996-09-16
JPH08269058A (ja)	1996-10-15
EP0732334A1 (fr)	1996-09-18
IL117455A0 (en)	1996-07-23
CN1140174A (zh)	1997-01-15
CA2171579A1 (en)	1996-09-14
NO961000D0 (no)	1996-03-12
HUP9600624A2 (en)	1997-01-28
KR960034205A (ko)	1996-10-22
HU9600624D0 (en)	1996-05-28
AU4800896A (en)	1996-09-26
ZA961994B (en)	1996-09-03

Publication	Publication Date	Title
DK174161B1 (da)	2002-07-29	Anellerede indolderivater, fremgangsmåde til deres fremstilling og fremgangsmåde til fremstilling af farmaceutisk præparat indeholdende dem
US5589476A (en)	1996-12-31	Imidazol-4-ylpiperidine derivatives, their preparation and their application in therapeutics
CZ75496A3 (en)	1996-10-16	Piperidine derivatives, process of their preparation, said derivatives as medicaments and pharmaceutical composition containing such derivatives
HU201544B (en)	1990-11-28	Process for production of derivatives of indol-2-ons, quinoline-2-ons, benzo/bazepin-2-ons, benzimidasole-2-ons and quinasoline-2-ons 1-hydroxi-2-piperidon-alkyl and medical compositions containing these derivatives
AU721102B2 (en)	2000-06-22	1H-pyrido{3,4-b}indole-4-carboxamide derivatives, their preparation and their application in therapeutics
NZ272961A (en)	1998-02-26	Pyrido[3,4-6]indol-2-one derivatives and medicaments thereof
US6552015B2 (en)	2003-04-22	Azabicycloalkane derivatives and therapeutic uses thereof
JP2001520231A (ja)	2001-10-30	ベンゾオキサジン誘導体、その製造およびその治療における適用
EP0496314B1 (en)	1997-10-01	Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[b]indoles and related compounds, intermediates and a process for the preparation thereof and their use as medicaments
PL191863B1 (pl)	2006-07-31	Tetrahydro-૪-karboliny
FR2832714A1 (fr)	2003-05-30	Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2747678A1 (fr)	1997-10-24	Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
US5663173A (en)	1997-09-02	N-[(1,4-diazabicyclo[2.2.2] oct-2-yl)methyl] benzamide derivatives, their preparations and their application in therapeutics
CZ139298A3 (cs)	1998-09-16	Amidinové a isothiomočovinové deriváty jako inhibitory synthasy oxidu dusičného
FI88162B (fi)	1992-12-31	Foerfarande foer framstaellning av terapeutiskt anvaendbara sulfonyldekahydro-8h-isokino/2,1-g//1,6/naftyridiner, deras optiska isomerer samt farmaceutiskt godtagbara salter
JP3615550B2 (ja)	2005-02-02	イミダゾ［１，５−ａ］インドール−３−オンのアザビシクロアルキル誘導体およびそれらの製造法
JPH10505333A (ja)	1998-05-26	イミダゾピリジン−アゾリジノン
EP1053235A1 (en)	2000-11-22	Oxazole derivatives as serotonin-1a receptor agonists
KR20090096748A (ko)	2009-09-14	아미노피롤로[１,２-ａ]인돌 및 아미노피리다지노[１,６-ａ]인돌 유도체, 및 이의 제조 방법 및 이를 포함하는 약제 조성물
US5198437A (en)	1993-03-30	1,7-annelated indolecarboxylic acid esters and amides
US5929085A (en)	1999-07-27	Amidine and isothiourea derivatives, compositions containing them and their use as inhibitors of nitric oxide synthase
CZ286945B6 (en)	2000-08-16	Tetracyclic azepine derivatives, process and intermediates for their preparation and pharmaceutical preparations based thereon
US5514700A (en)	1996-05-07	Substituted 1,2,3,4-tetrahydrocyclopent b!indoles, compositions and use
JPS63139183A (ja)	1988-06-10	置換ヘキサヒドロアリ−ルキノリジン類
FI89361C (fi)	1993-09-27	Foerfarande foer framstaellning av farmaceutiskt anvaendbart 5,6,7,8-tetrahydro-4h-isoxazolo/4,5-c/azepinderivat